119 related articles for article (PubMed ID: 9726054)
21. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate).
Mizutani T; Sugihara A; Nakamuro K; Terada N
J Clin Endocrinol Metab; 1998 Apr; 83(4):1253-5. PubMed ID: 9543151
[TBL] [Abstract][Full Text] [Related]
22. Transient shrinkage of a uterine leiomyosarcoma treated with GnRH agonist for a presumed uterine leiomyoma: comparison of magnetic resonance imaging finding before and during GnRH agonist treatment.
Kawamura N; Iwanaga N; Hada S; Maeda K; Sumi T; Ishiko O; Ogita S
Oncol Rep; 2001; 8(6):1255-7. PubMed ID: 11605044
[TBL] [Abstract][Full Text] [Related]
23. Fibroids (uterine myomatosis, leiomyomas).
Lethaby A; Vollenhoven B
Clin Evid; 2005 Dec; (14):2264-82. PubMed ID: 16620489
[No Abstract] [Full Text] [Related]
24. Fibroids (uterine myomatosis, leiomyomas).
Lethaby A; Vollenhoven B
Clin Evid; 2004 Dec; (12):2563-85. PubMed ID: 15865807
[No Abstract] [Full Text] [Related]
25. Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy.
Khurana KK; Singh SB; Tatum AH; Schulz V; Badawy SZ
J Reprod Med; 1999 Jun; 44(6):487-92. PubMed ID: 10394541
[TBL] [Abstract][Full Text] [Related]
26. Goserelin versus leuprolide before hysterectomy for uterine fibroids.
Lim SS; Sockalingam JK; Tan PC
Int J Gynaecol Obstet; 2008 May; 101(2):178-83. PubMed ID: 18164303
[TBL] [Abstract][Full Text] [Related]
27. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment.
Di Lieto A; De Rosa G; De Falco M; Iannotti F; Staibano S; Pollio F; Scaramellino M; Salvatore G
Hum Pathol; 2002 Feb; 33(2):220-4. PubMed ID: 11957148
[TBL] [Abstract][Full Text] [Related]
28. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment.
Ito F; Kawamura N; Ichimura T; Tsujimura A; Ishiko O; Ogita S
Fertil Steril; 2001 Jan; 75(1):125-30. PubMed ID: 11163826
[TBL] [Abstract][Full Text] [Related]
29. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma.
Abulafia O; Kleinhaus K; Levi G; Lee YC; Sherer DM
Gynecol Obstet Invest; 2001; 52(2):108-13. PubMed ID: 11586038
[TBL] [Abstract][Full Text] [Related]
30. Mesenchymal tumors of the uterine corpus with heterologous and hematopoietic components: a study of ten cases and review of the literature.
Kondi-Pafiti A; Grapsa D; Kairi-Vassilatou E; Kontogianni-Katsarou K; Koliopoulos C; Botsis D
Eur J Gynaecol Oncol; 2006; 27(1):73-7. PubMed ID: 16550975
[TBL] [Abstract][Full Text] [Related]
31. Association between magnetic resonance imaging findings of uterine leiomyomas and symptoms demanding treatment.
Ruuskanen AJ; Hippeläinen MI; Sipola P; Manninen HI
Eur J Radiol; 2012 Aug; 81(8):1957-64. PubMed ID: 21592711
[TBL] [Abstract][Full Text] [Related]
32. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.
Vu K; Greenspan DL; Wu TC; Zacur HA; Kurman RJ
Hum Pathol; 1998 Apr; 29(4):359-63. PubMed ID: 9563785
[TBL] [Abstract][Full Text] [Related]
33. [Pregnancy in nullipara after conservative excision of uterine cellular leiomyoma and supplementary GnRH analog therapy].
Cyrkowicz A; Fiala J; Wilkoszewski R
Ginekol Pol; 1998 Feb; 69(2):91-3. PubMed ID: 9591388
[TBL] [Abstract][Full Text] [Related]
34. Leiomyoma With Massive Lymphoid Infiltration: 2 Cases With Lymphocytic Vasculopathy and Angiocentric Germinal Centers.
Wong J; Roy SF; Provencher D; Maietta A; Rahimi K
Int J Gynecol Pathol; 2023 Mar; 42(2):155-158. PubMed ID: 35348475
[TBL] [Abstract][Full Text] [Related]
35. Uterine myoma after cessation of gonadotropin-releasing hormone agonist: ultrasound and histopathologic findings.
Wang PH; Yang AH; Yuan CC; Lee WL; Chao HT
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Nov; 61(11):625-9. PubMed ID: 9872018
[TBL] [Abstract][Full Text] [Related]
36. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy.
Marshall LA; Cain DF; Dmowski WP; Chesnut CH
Obstet Gynecol; 1996 Mar; 87(3):350-4. PubMed ID: 8598953
[TBL] [Abstract][Full Text] [Related]
37. Variable response of uterine leiomyomas after GnRH agonist therapy.
Brosens IA
Fertil Steril; 1997 Nov; 68(5):948-9. PubMed ID: 9389836
[No Abstract] [Full Text] [Related]
38. Ultrasound guided high-intensity focused ultrasound combined with gonadotropin releasing hormone analogue (GnRHa) ablating uterine leiomyoma with homogeneous hyperintensity on T
Yang S; Kong F; Hou R; Rong F; Ma N; Li S; Yang J
Br J Radiol; 2017 May; 90(1073):20160760. PubMed ID: 28256923
[TBL] [Abstract][Full Text] [Related]
39. Development of a Model for the Prediction of Treatment Response of Uterine Leiomyomas after Uterine Artery Embolization.
Chung YJ; Kang SY; Chun HJ; Rha SE; Cho HH; Kim JH; Kim MR
Int J Med Sci; 2018; 15(14):1771-1777. PubMed ID: 30588202
[No Abstract] [Full Text] [Related]
40. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
